MED Fundamental Analysis - MEDIFAST INC

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to MED. MED was compared to 36 industry peers in the Personal Care Products industry. No worries on liquidiy or solvency for MED as it has an excellent financial health rating, but there are worries on the profitability. MED has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MED has reported negative net income.

In the past year MED had a positive cash flow from operations.

In the past 5 years MED has always been profitable.

In the past 5 years MED always reported a positive cash flow from operatings.

1.2 Ratios

With a Return On Assets value of 0.09%, MED perfoms like the industry average, outperforming 47.22% of the companies in the same industry.

MED has a Return On Equity of 0.12%. This is comparable to the rest of the industry: MED outperforms 55.56% of its industry peers.

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROIC	N/A

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Profit Margin value of 0.06%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

MED's Profit Margin has declined in the last couple of years.

In the last couple of years the Operating Margin of MED has declined.

MED's Gross Margin of 72.44% is fine compared to the rest of the industry. MED outperforms 69.44% of its industry peers.

MED's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	0.06%
GM	72.44%

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MED does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MED has more shares outstanding

The number of shares outstanding for MED has been reduced compared to 5 years ago.

There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

MED has an Altman-Z score of 4.57. This indicates that MED is financially healthy and has little risk of bankruptcy at the moment.

MED has a better Altman-Z score (4.57) than 86.11% of its industry peers.

There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	4.57

ROIC/WACCN/A

WACC8.81%

2.3 Liquidity

A Current Ratio of 4.45 indicates that MED has no problem at all paying its short term obligations.

MED's Current ratio of 4.45 is amongst the best of the industry. MED outperforms 86.11% of its industry peers.

MED has a Quick Ratio of 3.95. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of MED (3.95) is better than 88.89% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.45
Quick Ratio	3.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.60%.

MED shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.59% yearly.

The Revenue for MED has decreased by -36.29% in the past year. This is quite bad

Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.

EPS 1Y (TTM)-100.6%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

3.2 Future

Based on estimates for the next years, MED will show a very negative growth in Earnings Per Share. The EPS will decrease by -43.69% on average per year.

Based on estimates for the next years, MED will show a very negative growth in Revenue. The Revenue will decrease by -23.25% on average per year.

EPS Next Y-78.11%

EPS Next 2Y-43.69%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED is on the same level as its industry peers.

		Industry Rank	Sector Rank
P/FCF	192.24
EV/EBITDA	-15.3

4.3 Compensation for Growth

MED's earnings are expected to decrease with -43.69% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-43.69%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MED has a Yearly Dividend Yield of 9.97%, which is a nice return.

Compared to an average industry Dividend Yield of 7.10, MED pays a better dividend. On top of this MED pays more dividend than 97.22% of the companies listed in the same industry.

Compared to an average S&P500 Dividend Yield of 2.31, MED pays a better dividend.

		Industry Rank	Sector Rank
Dividend Yield	9.97%

5.2 History

The dividend of MED decreases each year by -53.42%.

MED has been paying a dividend for over 5 years, so it has already some track record.

Dividend Growth(5Y)-53.42%

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.

The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.

DP78.63%

EPS Next 2Y-43.69%

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDIFAST INC

NYSE:MED (12/9/2025, 8:14:14 PM)

After market: 11.3 0 (0%)

11.3

-0.06 (-0.53%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)11-03 2025-11-03/amc

Earnings (Next)02-16 2026-02-16/amc

Inst Owners84.75%

Inst Owner Change7.25%

Ins Owners3.3%

Ins Owner Change5.24%

Market Cap124.19M

Revenue(TTM)429.69M

Net Income(TTM)248.00K

Analysts46.67

Price Target15.3 (35.4%)

Short Float %19.39%

Short Ratio12.11

Dividend

		Industry Rank	Sector Rank
Dividend Yield	9.97%

Yearly Dividend0.07

Dividend Growth(5Y)-53.42%

DP78.63%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)122.85%

Min EPS beat(2)46.69%

Max EPS beat(2)199.01%

EPS beat(4)4

Avg EPS beat(4)115.44%

Min EPS beat(4)46.69%

Max EPS beat(4)199.01%

EPS beat(8)6

Avg EPS beat(8)95.11%

EPS beat(12)10

Avg EPS beat(12)87.15%

EPS beat(16)13

Avg EPS beat(16)70.51%

Revenue beat(2)2

Avg Revenue beat(2)7.01%

Min Revenue beat(2)5.26%

Max Revenue beat(2)8.75%

Revenue beat(4)4

Avg Revenue beat(4)5.3%

Min Revenue beat(4)3.13%

Max Revenue beat(4)8.75%

Revenue beat(8)7

Avg Revenue beat(8)3.21%

Revenue beat(12)11

Avg Revenue beat(12)3.67%

Revenue beat(16)14

Avg Revenue beat(16)3.57%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)-82.22%

EPS NQ rev (3m)-82.22%

EPS NY rev (1m)147.31%

EPS NY rev (3m)147.31%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.29
P/FCF	192.24
P/OCF	17.26
P/B	0.58
P/tB	0.58
EV/EBITDA	-15.3

EPS(TTM)-0.01

EYN/A

EPS(NY)-0.13

Fwd EYN/A

FCF(TTM)0.06

FCFY0.52%

OCF(TTM)0.65

OCFY5.79%

SpS39.1

BVpS19.54

TBVpS19.54

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	0.06%
GM	72.44%
FCFM	0.15%

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)57.45%

ROCE(5y)70.54%

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

F-Score5

Asset Turnover1.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	46.9%
Cap/Sales	1.52%
Interest Coverage	N/A
Cash Conversion	89.73%
Profit Quality	260.48%
Current Ratio	4.45
Quick Ratio	3.95
Altman-Z	4.57

F-Score5

WACC8.81%

ROIC/WACCN/A

Cap/Depr(3y)86.65%

Cap/Depr(5y)168.74%

Cap/Sales(3y)0.96%

Cap/Sales(5y)1.15%

Profit Quality(3y)359.98%

Profit Quality(5y)250.42%

High Growth Momentum

Growth

EPS 1Y (TTM)-100.6%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

EPS Next Y-78.11%

EPS Next 2Y-43.69%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-120.14%

EBIT growth 3Y-55.18%

EBIT growth 5Y-26.54%

EBIT Next Year-105.07%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-99.63%

FCF growth 3Y-34.4%

FCF growth 5Y-25.51%

OCF growth 1Y-96.19%

OCF growth 3Y-36.26%

OCF growth 5Y-21.91%

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.

What is the valuation status for MED stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.

What is the profitability of MED stock?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.

Can you provide the expected EPS growth for MED stock?

The Earnings per Share (EPS) of MEDIFAST INC (MED) is expected to decline by -78.11% in the next year.

MEDIFAST INC (MED) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

What is the valuation status for MED stock?

What is the profitability of MED stock?

Can you provide the expected EPS growth for MED stock?